A study found that a blood test detecting ctDNA after surgery more accurately predicts recurrence and survival in patients with stage 3 colon cancer.

Even after surgery and chemotherapy, some cancers, like pancreatic and colorectal, maintain a foothold in the body and ...

Chordoma is a rare tumor characterized by poor prognosis, limited therapeutic options, and a high rate of recurrence. Despite ...

Investigators reviewed data from the SANO trial to assess long-term comparative effectiveness of active surveillance vs standard esophagectomy in patients with complete clinical response following ...

To evaluate the clinical benefit of extended endocrine therapy after 5 years of adjuvant treatment with LHRHa in premenopausal women with node-positive, HR-positive early breast cancer.

A NEW breast cancer therapy shown to significantly reduce the risk of cancer recurrence and improve disease-free survival in women is now available in Thailand.1-3 ...

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

One large study found that more advanced cases of colorectal cancer had a higher likelihood of returning. For example, if participants had stage 3 colon cancer, almost 25 percent experienced a ...

Tamoxifen was approved by the FDA in 1977 to treat advanced breast cancer. In 1998, the Early Breast Cancer Trialists’ Cooperative Group published results showing that tamoxifen was effective in ...